Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, Y.
Right arrow Articles by Mayer, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, Y.
Right arrow Articles by Mayer, L.
Vol. 2, 641-649, July 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Inhibition of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase Enhances Chemotherapeutic Effects on H460 Human Non-Small Cell Lung Cancer Cells through Activation of Apoptosis1

Yanping Hu, Marcel Bally, Wieslawa H. Dragowska and Lawrence Mayer2

Department of Advanced Therapeutics, British Columbia Cancer Agency [Y. H., M. B., W. H. D., L. M.], and Celator Technologies Inc. [M. B., L. M.], Vancouver, British Columbia, V5Z 4E6 Canada

2 To whom requests for reprints should be addressed, at Department of Advanced Therapeutics, British Columbia Cancer Agency, 601 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6. Phone: (604) 877-6098, extension 3153; Fax: (604) 877-6011; E-mail: lmayer{at}bccancer.bc.ca

The effects of Dox (Dox), paclitaxel (Taxol), and serum starvation on the regulation of XIAP (X-linked inhibitor of apoptosis), Bcl-2 phosphorylation, and apoptosis were evaluated in human H460 non-small cell lung cancer cells. Protein kinases that responded to these treatments as prosurvival elements in signal transduction were identified by simultaneously screening phosphorylation of protein kinases in H460 cells cultured in serum-free medium or treated with Dox. We demonstrated that Dox and Taxol induced apoptosis through down-regulation of XIAP and phosphorylation of Bcl-2 in a concentration-dependent manner without changing expression of Bcl-xL in H460 cells. These effects were paralleled by activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase protein. We identified that serum starvation and Dox reduced phosphorylation of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK), protein kinase C (PKC) {alpha}/ß and c-Jun NH2-terminal kinase. The MEK-specific inhibitor U0126 or PKC inhibitor staurosporine (STP) also down-regulated XIAP expression and induced apoptosis. Thus, our data suggest that apoptosis and down-regulation of XIAP induced by Dox exposure or serum starvation may be mediated through inactivation of the MEK/ERK and PKC{alpha}/ß pathways. In support of this we demonstrated that the cytotoxic effects of Dox when combined with U0126 or STP were enhanced, i.e., synergistic cytotoxic activities were demonstrated. The synergistic interaction of U0126 or STP with Dox was sequence- and concentration-dependent.




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Zanchi, V. Zuco, C. Lanzi, R. Supino, and F. Zunino
Modulation of Survival Signaling Pathways and Persistence of the Genotoxic Stress as a Basis for the Synergistic Interaction between the Atypical Retinoid ST1926 and the Epidermal Growth Factor Receptor Inhibitor ZD1839
Cancer Res., March 15, 2005; 65(6): 2364 - 2372.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. A. Fennell
Caspase Regulation in Non-Small Cell Lung Cancer and its Potential for Therapeutic Exploitation
Clin. Cancer Res., March 15, 2005; 11(6): 2097 - 2105.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
V. M. Pushkarev, D. V. Starenki, V. A. Saenko, H. Namba, J. Kurebayashi, M. D. Tronko, and S. Yamashita
Molecular Mechanisms of the Effects of Low Concentrations of Taxol in Anaplastic Thyroid Cancer Cells
Endocrinology, July 1, 2004; 145(7): 3143 - 3152.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Sumitomo, T. Asano, J. Asakuma, T. Asano, A. Horiguchi, and M. Hayakawa
ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway
Clin. Cancer Res., January 15, 2004; 10(2): 794 - 801.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.